Iovance Biotherapeutics
IOVA
153 hedge funds and large institutions have $1.12B invested in Iovance Biotherapeutics in 2019 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 37 increasing their positions, 49 reducing their positions, and 17 closing their positions.
461% more call options, than puts
Call options by funds: $1.33M | Put options by funds: $238K
94% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 17
10% more funds holding
Funds holding: 139 → 153 (+14)
6% more capital invested
Capital invested by funds: $1.05B → $1.12B (+$68.1M)
1.11% less ownership
Funds ownership: 96.25% → 95.14% (-1.1%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
24% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$11.6M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$11.1M |
| 3 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$8.08M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$7.82M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
+$4.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$24.2M |
| 2 |
BC
Broadfin Capital
New York
|
-$15.8M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$7.28M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$5.32M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.04M |
IOVA Hedge Fund Activity: Q1 2019 in Review
153 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q1 2019, worth a combined $1.12B — up 6.5% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new IOVA positions and 17 closed out — a net gain of 16 holders — while 37 added to existing stakes and 49 trimmed.
The largest buyer was HealthCor Management, opening a new position worth an estimated $11.6M. The largest seller was Citadel Advisors, cutting an estimated $24.2M.
- 153 institutional investors held Iovance Biotherapeutics (IOVA) as of Q1 2019, up from 139 in Q4 2018.
- Funds reported $1.12B of Iovance Biotherapeutics stock for Q1 2019, up 6.5% quarter-over-quarter.
- 33 funds opened new Iovance Biotherapeutics positions in Q1 2019 and 17 closed out, a net change of +16 holders.
- The largest Iovance Biotherapeutics buyer in Q1 2019 was HealthCor Management, an estimated $11.6M added.
- The largest Iovance Biotherapeutics seller in Q1 2019 was Citadel Advisors, an estimated $24.2M sold.
Based on aggregated 13F filings for Q1 2019.